实体瘤嵌合抗原受体T细胞临床试验全景——全面概述

Department of Dermatology, Universtitätsklinikum Erlangen, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Hartmannstraße 14, 91052 Erlangen, Germany.

Comprehensive Cancer Center Erlangen European Metropolitan Area of Nuremberg (CCC ER-EMN), Östliche Stadtmauerstraße 30, 91054 Erlangen, Germany.

Cancers (Basel). 2020 Sep 9;12(9):2567. doi: 10.3390/cancers12092567.

CAR-T cells showed great potential in the treatment of patients with hematologic tumors. However, the clinical efficacy of CAR-T cells against solid tumors lags behind. To obtain a comprehensive overview of the landscape of CAR-T cell clinical trials against this type of cancer, this review summarizes all the 196 studies registered at clinicaltrials.gov. Special focus is on: (1) geographical distribution; (2) targeted organs, tumor entities, and antigens; (3) CAR transfer methods, CAR formats, and extra features introduced into the T cells; and (4) patient pretreatments, injection sites, and safety measurements. Finally, the few data on clinical outcome are reported. The last assessment of clinicaltrials.gov for the data summarized in this paper was on 4 August 2020.

嵌合抗原受体T细胞（CAR-T细胞）在血液系统肿瘤患者的治疗中显示出巨大潜力。然而，CAR-T细胞治疗实体瘤的临床疗效滞后。为全面了解针对此类癌症的CAR-T细胞临床试验概况，本综述总结了在clinicaltrials.gov上注册的所有196项研究。特别关注：（1）地理分布；（2）靶向器官、肿瘤实体和抗原；（3）CAR转导方法、CAR形式以及引入T细胞的额外特征；（4）患者预处理、注射部位和安全措施。最后，报告了关于临床结果的少量数据。clinicaltrials.gov对本文总结数据的最后评估时间为2020年8月4日。